The expensive rare disease therapy Spinraza has quickly become a critical part of Biogen’s performance, but the latest sales figures were sluggish.
MarketWatch.com - Top Stories, MarketWatch
Wed, 04/25/2018 - 4:28am
The expensive rare disease therapy Spinraza has quickly become a critical part of Biogen’s performance, but the latest sales figures were sluggish.